amlodipine and Left Ventricular Hypertrophy studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Research Excerpts

Excerpt	Relevance	Reference
"In this prospective open-label study, 92 patients with essential hypertension were randomized to treatment with a TFC of perindopril/indapamide/amlodipine at different doses or a triple free combination therapy (FCT) including ACEI/diuretic/CCB."	9.30	Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects. ( Lenti, S; Mazza, A; Rigatelli, G; Rossetti, C; Rubello, D; Schiavon, L; Torin, G; Townsend, DM, 2019)
"5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks."	9.19	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014)
"The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH."	9.16	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension."	9.15	Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011)
"This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function."	9.15	The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011)
" The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension."	9.14	Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009)
"Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia."	9.13	Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008)
"Amlodipine treatment in patients with hypertension significantly reduced the LV mass index and LV posterior wall thickness, without notably affecting the LV end-diastolic diameter."	9.12	Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis. ( Gao, Y; Yang, P; Zhou, D, 2021)
"The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction."	9.12	Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006)
"To compare the effects of the angiotensin receptor blocker (ARB) valsartan versus the calcium channel blocker amlodipine, reactive oxygen species (ROS) formation by monocytes, C-reactive protein (CRP), and left ventricular (LV) mass were studied in 104 hypertensive patients with left ventricular hypertrophy (LVH)."	9.11	Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. ( Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J, 2004)
" Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)."	9.10	Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002)
"A 9-month, double-blind, randomized study was performed in 202 patients with LVH and hypertension who received eplerenone 200 mg daily, enalapril 40 mg daily, or eplerenone 200 mg and enalapril 10 mg daily."	9.10	Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003)
"The aim of this study was to comparatively assess the effects of irbesartan and amlodipine monotherapies on left ventricular mass index (LVMI) in patients with mild to moderate untreated hypertension and echocardiographically determined left ventricular hypertrophy (LVH)."	9.10	Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. ( Fedele, F; Fera, MS; Ferri, FM; Gaudio, C; Giovannini, M; Pannarale, G; Puddu, PE; Vittore, A; Vizza, CD, 2003)
"This was a 20-week, open-label, uncontrolled clinical investigation of the long-acting calcium antagonist amlodipine in 33 male or female patients with essential hypertension and left ventricular hypertrophy (LVH)."	9.09	Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. ( Ebanks, M; Ihenacho, HN; Islim, IF; Singh, SP; Watson, RD, 2001)
" After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12."	9.09	Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999)
"Amlodipine has a beneficial effect on LVH and also is an effective and safe drug to treat mild to moderate hypertension."	9.08	[Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]. ( Hoyos, M; Justo, E; Moreno, R; Oliván, J; Pérez Cano, R; Pizarro, JL; Ramos, E; Rodríguez, A, 1996)
" The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy."	7.74	Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007)
"Amlodipine prevents the left ventricular remodeling process accompanied by systolic and diastolic dysfunction, and inhibits abnormal cardiac gene expression after myocardial infarction."	7.70	Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. ( Iwao, H; Kim, S; Omura, T; Shimada, T; Takemoto, Y; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 1998)
"The dihydropyridine calcium channel blocking agent amlodipine is an effective anti-hypertensive agent and its use (in doses of 5 or 10 mg/day/kg body weight) was investigated in male Wistar rats with hypertension induced by aortic constriction."	7.69	Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. ( Patel, VB; Preedy, VR; Richardson, PJ; Sherwood, R; Siddiq, T, 1997)
"In a 3-month, open-label study, 54 consecutive black patients with very severe hypertension were treated with amlodipine."	7.69	Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. ( Chautsane, Z; Chopamba, A; Lee, A; Reddy, K; Sareli, P; Skoularigis, J; Strugo, V; Weinberg, J, 1995)
"Azelnidipine has beneficial effects on LV mass regression, transmitral flow, tissue Doppler, and LV longitudinal strain that are comparable to those of amlodipine on the same parameters."	6.79	Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. ( Ikeda, U; Izawa, A; Koyama, J; Miyashita, Y; Motoki, H; Takahashi, M; Tomita, T, 2014)
"The benefit of treating hypertension has been proven, but cardiovascular morbidity and mortality rates remain high."	6.69	The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. ( Julius, S; Mann, J, 1998)
"In this prospective open-label study, 92 patients with essential hypertension were randomized to treatment with a TFC of perindopril/indapamide/amlodipine at different doses or a triple free combination therapy (FCT) including ACEI/diuretic/CCB."	5.30	Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects. ( Lenti, S; Mazza, A; Rigatelli, G; Rossetti, C; Rubello, D; Schiavon, L; Torin, G; Townsend, DM, 2019)
"A total of 33,357 patients (aged ≥ 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril."	5.24	Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ( Bang, CN; Davis, BR; Devereux, RB; Okin, PM; Simpson, LM; Soliman, EZ, 2017)
"5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks."	5.19	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014)
"Losartan provided a greater attenuation of left ventricular hypertrophy than amlodipine, seemingly as a result of a greater reduction of myocardial fibrosis."	5.16	Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH."	5.16	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function."	5.15	The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011)
"The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension."	5.15	Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011)
" The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension."	5.14	Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009)
"BP control with ramipril or amlodipine could not provide adequate protection for development or progression of atherosclerosis and eccentric type of LVH in nondiabetic HD patients."	5.14	Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. ( Akinci, D; Altun, B; Kahraman, S; Ozer, N; Turgan, C; Yilmaz, R, 2010)
"Hypotensive and cardioprotective effects of amlodipine (normodipine) were evaluated in 65 patients (35 men and 30 women) with grade II essential arterial hypertension treated with regard for calcium-controlling parathyroid function."	5.14	[Efficacy of calcium antagonists depending on the functional state of parathyroid glands in patients with hypertensive disease]. ( Burmistrova, LF; Iskenderov, BG; Lokhina, TV; Sisina, ON, 2009)
"Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia."	5.13	Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008)
"Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare's Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol-based regimen in the population studied."	5.13	Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008)
"Amlodipine treatment in patients with hypertension significantly reduced the LV mass index and LV posterior wall thickness, without notably affecting the LV end-diastolic diameter."	5.12	Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis. ( Gao, Y; Yang, P; Zhou, D, 2021)
"The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction."	5.12	Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006)
"In the treatment of hypertension in subjects of African origins, although hydrochlorothiazide (HCTZ) is not as effective as calcium channel blockers, indapamide is superior to HCTZ."	5.11	Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry. ( Candy, GP; Essop, MR; Hlatshwayo, NM; Kachope, J; Libhaber, CD; Libhaber, EN; Norton, GR; Puane, MO; Sareli, P; Sliwa, K; Woodiwiss, AJ, 2004)
"To compare the effects of the angiotensin receptor blocker (ARB) valsartan versus the calcium channel blocker amlodipine, reactive oxygen species (ROS) formation by monocytes, C-reactive protein (CRP), and left ventricular (LV) mass were studied in 104 hypertensive patients with left ventricular hypertrophy (LVH)."	5.11	Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. ( Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J, 2004)
" Patients with essential hypertension were randomly assigned to receive either amlodipine, cilnidipine or nifedipine CR (which does not block N-type calcium channels) for 6 months."	5.10	Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. ( Shigematsu, M; Takami, T, 2003)
"The aim of this study was to comparatively assess the effects of irbesartan and amlodipine monotherapies on left ventricular mass index (LVMI) in patients with mild to moderate untreated hypertension and echocardiographically determined left ventricular hypertrophy (LVH)."	5.10	Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. ( Fedele, F; Fera, MS; Ferri, FM; Gaudio, C; Giovannini, M; Pannarale, G; Puddu, PE; Vittore, A; Vizza, CD, 2003)
"A 9-month, double-blind, randomized study was performed in 202 patients with LVH and hypertension who received eplerenone 200 mg daily, enalapril 40 mg daily, or eplerenone 200 mg and enalapril 10 mg daily."	5.10	Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003)
" Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)."	5.10	Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002)
" After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12."	5.09	Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999)
"This was a 20-week, open-label, uncontrolled clinical investigation of the long-acting calcium antagonist amlodipine in 33 male or female patients with essential hypertension and left ventricular hypertrophy (LVH)."	5.09	Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. ( Ebanks, M; Ihenacho, HN; Islim, IF; Singh, SP; Watson, RD, 2001)
"As part of the Amlodipine Cardiovascular Community Trial (ACCT), which was a large multicenter study designed to assess the effects of the calcium channel blocker amlodipine besylate (Norvasc) as monotherapy for treatment of mild to moderate hypertension, we sought to determine the effects of amlodipine on regression of left ventricular (LV) hypertrophy (LVH)."	5.08	Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. ( DiBona, GF; Gaffney, M; Kloner, RA; Sowers, JR; Wein, M, 1995)
"Amlodipine has a beneficial effect on LVH and also is an effective and safe drug to treat mild to moderate hypertension."	5.08	[Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]. ( Hoyos, M; Justo, E; Moreno, R; Oliván, J; Pérez Cano, R; Pizarro, JL; Ramos, E; Rodríguez, A, 1996)
"Spontaneously hypertensive rats (SHR) was used to study left ventricular hypertrophy (LVH) and its dynamic change after the interventions with Telmisartan and Amlodipine."	3.81	TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats. ( Chen, L; Hong, H; Lin, X; Shi, X; Wu, Y; Zou, G, 2015)
" The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy."	3.74	Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007)
"Our objective was to examine the effect of chronic treatment with amlodipine on blood pressure, left ventricular hypertrophy, and fibrosis in spontaneously hypertensive rats and the persistence of such an effect after drug withdrawal."	3.72	Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. ( Ardanaz, N; Arévalo, MA; Carrón, R; Guerrero, EI; Montero, MJ; San Román, L; Sevilla, MA; Voces, F, 2004)
"Amlodipine prevents the left ventricular remodeling process accompanied by systolic and diastolic dysfunction, and inhibits abnormal cardiac gene expression after myocardial infarction."	3.70	Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. ( Iwao, H; Kim, S; Omura, T; Shimada, T; Takemoto, Y; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 1998)
"We investigated the ability of the angiotensin converting enzyme (ACE) inhibitor imidapril hydrochloride, and of the calcium channel blocker amlodipine besilate, to prevent nephrosclerosis and left ventricular hypertrophy (LVH) in rats with hypertension induced by chronic inhibition of nitric oxide (NO)."	3.70	Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. ( Akuzawa, N; Hoshino, J; Kurashina, T; Nagai, R; Nakamura, T; Ono, Z; Saito, Y; Sakamoto, H; Sumino, H, 1998)
" lisinopril) in reducing chronic left ventricular hypertrophy in 15-week old spontaneously hypertensive rats (SHR)."	3.69	Protein synthesis in the hypertrophied heart of spontaneously hypertensive rats and a comparison of the effects of an ACE-inhibitor and a calcium channel antagonist. ( Patel, VB; Preedy, VR; Richardson, PJ; Siddiq, T, 1995)
"Using digitized M-mode echocardiograms and 24-hour noninvasive ambulatory blood pressure monitoring, we evaluated the effects of 1 year treatment with amlodipine on left ventricular morphology and function in 10 hypertensives with left ventricular hypertrophy."	3.69	One-year antihypertensive treatment with amlodipine: effects on 24-hour blood pressure and left ventricular anatomy and function. ( Bignotti, M; Gaudio, G; Grandi, AM; Guasti, L; Venco, A, 1995)
"In a 3-month, open-label study, 54 consecutive black patients with very severe hypertension were treated with amlodipine."	3.69	Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. ( Chautsane, Z; Chopamba, A; Lee, A; Reddy, K; Sareli, P; Skoularigis, J; Strugo, V; Weinberg, J, 1995)
"The dihydropyridine calcium channel blocking agent amlodipine is an effective anti-hypertensive agent and its use (in doses of 5 or 10 mg/day/kg body weight) was investigated in male Wistar rats with hypertension induced by aortic constriction."	3.69	Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. ( Patel, VB; Preedy, VR; Richardson, PJ; Sherwood, R; Siddiq, T, 1997)
"Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )."	2.90	Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019)
"Azelnidipine has beneficial effects on LV mass regression, transmitral flow, tissue Doppler, and LV longitudinal strain that are comparable to those of amlodipine on the same parameters."	2.79	Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. ( Ikeda, U; Izawa, A; Koyama, J; Miyashita, Y; Motoki, H; Takahashi, M; Tomita, T, 2014)
"Despite regression of left ventricular hypertrophy, there was no associated improvement in diastolic function."	2.79	Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. ( Baksi, AJ; Barron, AJ; Fitzgerald, D; Hughes, AD; Jabbour, RJ; Mayet, J; O'Brien, E; Poulter, N; Sever, P; Sharp, A; Stanton, A; Surendran, P; Thom, S, 2014)
"Treatment with olmesartan/azelnidipine for 2 years resulted in greater improvements in CBP, LVMI, and LV diastolic function, and arterial stiffness compared with olmesartan/amlodipine."	2.78	Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial. ( Saito, Y; Takami, T, 2013)
"The Assessment of Lotrel in Left Ventricular Hypertrophy and Hypertension Study compared a single-pill combination of amlodipine/benazepril at doses 5."	2.74	Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. ( Devereux, RB; Hall, D; Hilkert, R; Pitt, B; Purkayastha, D; Reichek, N; Rocha, RA, 2009)
"Left ventricular hypertrophy was present among <4% of the enrolled patients."	2.74	EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. ( Desai, A; Hassanein, A; Hilkert, R; Izzo, J; Oparil, S; Pitt, B; Rocha, R; Seifu, Y; Solomon, S; Verma, A, 2009)
"In 404 patients with left ventricular hypertrophy, a significantly larger decrease in left ventricular mass index 3 years after enrollment was observed in candesartan-based (n = 205) than amlodipine-based (n = 199) regimens (-22."	2.73	ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. ( Fujimoto, A; Nakao, K; Ogihara, T; Saruta, T, 2008)
"In conclusion, left ventricular hypertrophy, a major cardiovascular risk factor, was decreased to a significantly greater extent by rigorous than standard BP control."	2.70	Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. ( Brosnahan, G; Chapman, A; Ecder, T; Edelstein, C; Johnson, A; McFann, K; Schrier, R; Tison, L, 2002)
"The benefit of treating hypertension has been proven, but cardiovascular morbidity and mortality rates remain high."	2.69	The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. ( Julius, S; Mann, J, 1998)
"Reversal of left ventricular hypertrophy has been shown to improve left ventricular diastolic function in elderly patients with hypertension, but little is known about whether this affects physical performance."	2.68	Physical performance is preserved after regression of left ventricular hypertrophy. ( Cléroux, J; Lacourcière, Y; Poirier, L, 1997)
" Although the overall goal of these drugs remains the blockade of RAS activation, their individual targets in this system vary and may substantially influence the clinical benefit derived from the long term use of these substances."	2.45	Angiotensin II type 1 receptor blockade: high hopes sent back to reality? ( Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B, 2009)
" We have now compared the effects of the ARB valsartan combined with cilnidipine or amlodipine on cardiac pathophysiology in DS rats."	1.42	Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. ( Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S, 2015)
"Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)."	1.38	Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012)
"Cardiac complications were defined as left ventricular hypertrophy (LVH) and ischemic heart disease (IHD)."	1.35	Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. ( Fujimoto, A; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2009)
"Malignant hypertension is a well-defined condition associated with high blood pressure and acute target-organ damage."	1.33	Malignant hypertension with intestinal ischemia secondary to juxtaglomerular cell tumor. ( Leitão, AA; Leite, CA; Libório, AB; Marques, Fde O; Praxedes, JN; Testagrossa, L, 2005)
"The transgenics developed left ventricular hypertrophy along with perivascular and interstitial fibrosis which became progressively worse up to 24 weeks of age."	1.31	Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. ( Bishop, JE; Gohlke, P; Kiernan, LA; McEwan, JR; Montgomery, HE, 2000)
"Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it."	1.30	[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999)
"Forearm vasodilatory response to reactive hyperemia was improved by temocapril (102 +/- 20% to 168 +/- 25%, P < ."	1.30	Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. ( Hata, T; Higaki, J; Iwatsubo, H; Kumamoto, K; Morita, R; Nagano, M; Ogihara, T; Sakai, T, 1997)

Research

Studies (89)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	19 (21.35)	18.2507
2000's	41 (46.07)	29.6817
2010's	26 (29.21)	24.3611
2020's	3 (3.37)	2.80

Authors	Studies
Gao, Y	1
Zhou, D	1
Yang, P	1
Youssef, AM	1
Elghoneimy, HA	1
Helmy, MW	1
Abdelazeem, AM	1
El-Khodary, NM	1
Mazza, A	1
Townsend, DM	1
Schiavon, L	1
Torin, G	1
Lenti, S	1
Rossetti, C	1
Rigatelli, G	1
Rubello, D	1
Morselli, F	1
Fang, L	1
Ambrosini, I	1
Chowienczyk, PJ	1
Faconti, L	1
Bang, CN	1
Soliman, EZ	2
Simpson, LM	2
Davis, BR	4
Devereux, RB	2
Okin, PM	2
Johnson, K	1
Oparil, S	3
Tereshchenko, LG	1
Takami, T	3
Saito, Y	3
Barron, AJ	1
Hughes, AD	1
Sharp, A	1
Baksi, AJ	1
Surendran, P	1
Jabbour, RJ	1
Stanton, A	1
Poulter, N	1
Fitzgerald, D	1
Sever, P	1
O'Brien, E	1
Thom, S	1
Mayet, J	1
Motoki, H	1
Koyama, J	1
Izawa, A	1
Tomita, T	1
Miyashita, Y	1
Takahashi, M	2
Ikeda, U	1
Azizi, M	1
Perdrix, L	1
Bobrie, G	1
Frank, M	1
Chatellier, G	1
Ménard, J	1
Plouin, PF	1
Nagasawa, K	1
Takahashi, K	1
Matsuura, N	1
Takatsu, M	1
Hattori, T	1
Watanabe, S	1
Harada, E	1
Niinuma, K	1
Murohara, T	1
Nagata, K	1
Ripley, DP	1
Negrou, K	1
Oliver, JJ	1
Worthy, G	1
Struthers, AD	1
Plein, S	1
Greenwood, JP	1
Zou, G	1
Hong, H	1
Lin, X	1
Shi, X	1
Wu, Y	1
Chen, L	1
Ernst, ME	1
Prineas, RJ	1
Ghosh, A	1
Cushman, WC	2
Einhorn, PT	1
Grimm, RH	2
Ostroumova, OD	1
Kochetkov, AI	1
Ogihara, T	4
Fujimoto, A	3
Nakao, K	3
Saruta, T	3
Ueshima, K	2
Yasuno, S	1
Oba, K	1
Tsutamoto, T	1
Tanaka, T	1
Nishiyama, K	1
Yamaji, M	1
Kawahara, C	1
Fujii, M	1
Yamamoto, T	1
Horie, M	1
Iskenderov, BG	1
Burmistrova, LF	1
Sisina, ON	1
Lokhina, TV	1
Rosendorff, C	1
Dubiel, R	1
Xu, J	1
Chavanu, KJ	1
Futai, R	1
Ito, T	1
Kawanishi, Y	1
Terasaki, F	1
Kitaura, Y	1
Hassanein, A	1
Desai, A	1
Verma, A	1
Izzo, J	1
Rocha, R	1
Hilkert, R	2
Seifu, Y	1
Pitt, B	3
Solomon, S	1
Reichek, N	2
Rocha, RA	1
Hall, D	1
Purkayastha, D	1
Grothusen, A	1
Divchev, D	1
Luchtefeld, M	1
Schieffer, B	1
Yilmaz, R	1
Altun, B	1
Kahraman, S	1
Ozer, N	1
Akinci, D	1
Turgan, C	1
Yoshida, C	1
Goda, A	1
Naito, Y	1
Nakaboh, A	1
Matsumoto, M	1
Otsuka, M	1
Ohyanagi, M	1
Hirotani, S	1
Lee-Kawabata, M	1
Tsujino, T	1
Masuyama, T	1
Kukushkin, SK	1
Manoshkina, EM	1
Yamamoto, K	2
Ozaki, H	1
Takayasu, K	1
Akehi, N	1
Fukui, S	1
Sakai, A	1
Kodama, M	1
Shimonagata, T	1
Kobayashi, K	1
Ota, M	1
Horiguchi, Y	1
Ebisuno, S	1
Katsube, Y	1
Yamazaki, T	1
Ohtsu, H	1
Hori, M	2
Matsuno, Y	1
Minatoguchi, S	1
Fujiwara, H	1
Tomiyama, H	1
Yoshida, M	1
Yamada, J	1
Matsumoto, C	1
Odaira, M	1
Shiina, K	1
Yamashina, A	1
Fogari, R	2
Mugellini, A	2
Destro, M	1
Corradi, L	1
Lazzari, P	1
Zoppi, A	2
Preti, P	2
Derosa, G	2
Shang, W	1
Han, P	1
Yang, CB	1
Gu, XW	1
Zhang, W	1
Xu, LP	1
Fu, ST	1
Su, DF	1
Xie, HH	1
Takano, H	1
Hasegawa, H	1
Narumi, H	1
Shindo, S	1
Mizuma, H	1
Kuwabara, Y	1
Kobayashi, Y	1
Komuro, I	1
Maffioli, P	1
Nagashima, A	1
Watanabe, R	1
Ogawa, M	1
Suzuki, J	1
Masumura, M	1
Hishikari, K	1
Shimizu, T	1
Takayama, K	1
Hirata, Y	1
Nagai, R	2
Isobe, M	1
Peng, F	1
Lin, J	1
Lin, L	1
Tang, H	1
Shibasaki, Y	2
Nishiue, T	2
Masaki, H	2
Matsubara, H	2
Iwasaka, T	2
Messerli, FH	1
Scott, I	1
Stowasser, M	1
Willenbrock, R	1
Zannad, F	1
Phillips, RA	1
Roniker, B	1
Kleiman, J	1
Krause, S	1
Burns, D	1
Williams, GH	1
Gaudio, C	1
Ferri, FM	1
Giovannini, M	1
Pannarale, G	1
Puddu, PE	1
Vittore, A	1
Fera, MS	1
Vizza, CD	1
Fedele, F	1
Shigematsu, M	1
Neutel, JM	1
Smith, DH	1
Weber, MA	1
Libhaber, EN	1
Libhaber, CD	1
Candy, GP	1
Sliwa, K	1
Kachope, J	1
Hlatshwayo, NM	1
Puane, MO	1
Woodiwiss, AJ	1
Norton, GR	1
Essop, MR	1
Sareli, P	2
Yasunari, K	1
Maeda, K	1
Watanabe, T	1
Nakamura, M	1
Yoshikawa, J	2
Asada, A	1
Sevilla, MA	1
Voces, F	1
Carrón, R	1
Guerrero, EI	1
Ardanaz, N	1
San Román, L	1
Arévalo, MA	1
Montero, MJ	1
Ogimoto, A	1
Mizobuchi, T	1
Shigematsu, Y	1
Hara, Y	1
Ohtsuka, T	1
Fukuoka, T	1
Okura, T	1
Higaki, J	2
Bilge, AK	1
Atilgan, D	1
Tükek, T	1
Ozcan, M	1
Ozben, B	1
Koylan, N	1
Meriç, M	1
Ikeda, T	2
Gomi, T	2
Shibuya, Y	2
Matsuo, K	1
Kosugi, T	1
Oku, N	1
Uetake, Y	1
Kinugasa, S	1
Furutera, R	1
Ishimitsu, T	1
Kobayashi, T	1
Honda, T	1
Minami, J	1
Ohta, S	1
Inada, H	1
Yoshii, M	1
Ono, H	1
Matsuoka, H	1
Libório, AB	1
Marques, Fde O	1
Testagrossa, L	1
Leite, CA	1
Leitão, AA	1
Praxedes, JN	1
Leenen, FH	2
Nwachuku, CE	1
Black, HR	1
Alderman, MH	1
Atlas, SA	1
Basile, JN	1
Cuyjet, AB	1
Dart, R	1
Felicetta, JV	1
Haywood, LJ	1
Jafri, SZ	1
Proschan, MA	1
Thadani, U	1
Whelton, PK	1
Wright, JT	1
Staessen, JA	1
Hansen, TW	1
Birkenhäger, WH	1
Lindgren, P	1
Buxton, M	1
Kahan, T	1
Poulter, NR	1
Dahlöf, B	1
Sever, PS	1
Wedel, H	1
Jönsson, B	1
Arslanagić, A	1
Bajraktarević, A	1
Shinozaki, S	1
Suzuki, Y	1
Matsuda, N	1
Ge, CJ	1
Lu, SZ	1
Chen, YD	1
Wu, XF	1
Hu, SJ	1
Ji, Y	1
Patel, VB	3
Siddiq, T	2
Richardson, PJ	3
Preedy, VR	3
Bignotti, M	1
Grandi, AM	1
Gaudio, G	1
Guasti, L	1
Venco, A	1
Ruvolo, G	1
Greco, E	1
Speziale, G	1
Di Natale, M	1
Marino, B	1
Arita, M	1
Horinaka, S	1
Frohlich, ED	1
Staessen, J	1
Amery, A	1
Paice, AG	1
Kloner, RA	1
Sowers, JR	1
DiBona, GF	1
Gaffney, M	1
Wein, M	1
Skoularigis, J	1
Strugo, V	1
Weinberg, J	1
Chopamba, A	1
Chautsane, Z	1
Lee, A	1
Reddy, K	1
Fourney, A	1
Cicco, G	1
Dolce, E	1
Gigante, G	1
Pirrelli, A	1
Oliván, J	1
Moreno, R	1
Hoyos, M	1
Ramos, E	1
Rodríguez, A	1
Pizarro, JL	1
Justo, E	1
Pérez Cano, R	1
Iwatsubo, H	1
Nagano, M	1
Sakai, T	1
Kumamoto, K	1
Morita, R	1
Hata, T	1
Sherwood, R	1
Lacourcière, Y	1
Poirier, L	1
Cléroux, J	1
Akuzawa, N	1
Nakamura, T	1
Kurashina, T	1
Hoshino, J	1
Sakamoto, H	1
Sumino, H	1
Ono, Z	1
Shimada, T	1
Yoshiyama, M	1
Takeuchi, K	1
Omura, T	1
Takemoto, Y	1
Kim, S	1
Iwao, H	1
Mann, J	1
Julius, S	1
Anguita Sánchez, M	1
Martina, B	1
Dieterle, T	1
Weinbacher, M	1
Battegay, E	1
Bishop, JE	1
Kiernan, LA	1
Montgomery, HE	1
Gohlke, P	1
McEwan, JR	1
Sandmann, S	1
Claas, R	1
Cleutjens, JP	1
Daemen, MJ	1
Unger, T	1
Terpstra, WF	1
May, JF	1
Smit, AJ	1
de Graeff, PA	1
Havinga, TK	1
van den Veur, E	1
Schuurman, FH	1
Meyboom-de Jong, B	1
Crijns, HJ	1
Islim, IF	1
Watson, RD	1
Ihenacho, HN	1
Ebanks, M	1
Singh, SP	1
Oikarinen, L	1
Viitasalo, M	1
Toivonen, L	1
Nieminen, MS	1
Yu, G	1
Liang, X	1
Xie, X	1
Su, M	1
Zhao, S	1
Nishikawa, M	1
Schrier, R	1
McFann, K	1
Johnson, A	1
Chapman, A	1
Edelstein, C	1
Brosnahan, G	1
Ecder, T	1
Tison, L	1
Spencer, CG	1
Gurney, D	1
Blann, AD	1
Beevers, DG	1
Lip, GY	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.[NCT04085562]	Phase 4	46 participants (Actual)	Interventional	2019-09-01	Completed
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055]	Phase 4	75 participants (Anticipated)	Interventional	2023-08-25	Recruiting
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension[NCT00139555]	Phase 4	125 participants (Actual)	Interventional	2004-07-31	Completed
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060]	Phase 4	53 participants (Actual)	Interventional	2007-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Atrial Dimension (in mm)

Intervention	micrograms/L (Mean)
	Baseline (PINP)	12 Months (PINP)	Baseline (PIIINP)	12 Months (PIIINP)	Baseline (ICTP)	12 Months (ICTP)
Placebo Control	2.1	0.6	4.5	1.6	2.5	-2.3
Spironolactone	2.1	0.7	4.7	2.0	2.2	2.7

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Ventricular End-Diastolic (LVED) Cavity Size (in mm/m^2)

Intervention	millimeters (Mean)
	Left Atrial Dimension (Baseline)	Left Atrial Dimension (12-Month Follow-Up)
Placebo Control	41	40
Spironolactone	40	40

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Maximum Left Ventricular Wall Thickness (in mm)

Intervention	mm/m^2 (Mean)
	LVED Cavity Size (Baseline)	LVED Cavity Size (12-Month Follow-Up)
Placebo Control	145	146
Spironolactone	133	129

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Percentage of Left Ventricular Mass (%LV)

Intervention	millimeters (Mean)
	Maximum Left Ventricular Wall Thickness (Baseline)	Maximum Left Ventricular Wall Thickness (12-Month Follow-Up)
Placebo Control	21	19
Spironolactone	22	22

Measure of Functional Capacity: Peak Oxygen Consumption With Exercise

Intervention	Percentage of Total LV Mass (Mean)
	LGE Assessment of Myocardial Fibrosis (Baseline)	LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up)
Placebo Control	2.5	2.8
Spironolactone	1.1	1.8

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

Measure of Heart Failure Symptoms According to the New York Heart Association Functional Class

Intervention	ml/kg/min (Mean)
	Peak VO2 (Baseline)	Peak VO2 (12-Month Follow-Up)
Placebo Control	28	29
Spironolactone	30	29

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)

Measure of Indices of Diastolic Function by Tissue Doppler Echocardiography (Septal E/e')

Intervention	score on a scale (Mean)
	NYHA Class (Baseline)	NYHA Class (12-Month Follow Up)
Placebo Control	1.5	1.6
Spironolactone	1.6	1.7

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

Article	Year
Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis. Annals of palliative medicine, 2021, Volume: 10, Issue:10 Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Hypertrophy, Lef	2021
Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva cardioangiologica, 2009, Volume: 57, Issue:6 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih	2009
[Amlodipine in contemporary therapy of cardiovascular diseases]. Kardiologiia, 2010, Volume: 50, Issue:10 Topics: Amlodipine; Biotransformation; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Hyper	2010
Evolution of calcium antagonists: past, present, and future. Clinical cardiology, 2003, Volume: 26, Issue:2 Suppl 2 Topics: Amlodipine; Calcium Channel Blockers; Diabetic Angiopathies; Edema; Humans; Hypertension; Hypertroph	2003
[J-ELAN study (effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension)]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Apr-28, Volume: 65 Suppl 4 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke	2007

Article	Year
Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial. Medicine, 2021, Dec-23, Volume: 100, Issue:51 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Female; Humans; Hypert	2021
Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 120 Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Combinations; Female; Follow	2019
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. American journal of hypertension, 2017, Sep-01, Volume: 30, Issue:9 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Disease P	2017
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. Journal of the American Heart Association, 2019, 04-16, Volume: 8, Issue:8 Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography	2019
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. Journal of the American Heart Association, 2019, 04-16, Volume: 8, Issue:8 Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography	2019
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. Journal of the American Heart Association, 2019, 04-16, Volume: 8, Issue:8 Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography	2019
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. Journal of the American Heart Association, 2019, 04-16, Volume: 8, Issue:8 Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography	2019
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial. Drug design, development and therapy, 2013, Volume: 7 Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Diastole; Dihydropyridines; Drug Therapy, Combination; F	2013
Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:2 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Drug Therapy, Combi	2014
Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography (Mount Kisco, N.Y.), 2014, Volume: 31, Issue:10 Topics: Adult; Aged; Amlodipine; Analysis of Variance; Azetidinecarboxylic Acid; Calcium Channel Blockers; D	2014
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. Journal of hypertension, 2014, Volume: 32, Issue:10 Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers	2014
Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study. Clinical and experimental hypertension (New York, N.Y. : 1993), 2015, Volume: 37, Issue:4 Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aorta, Th	2015
Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of the American Society of Hypertension : JASH, 2016, Volume: 10, Issue:12 Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Electrocardiography; Female; Humans; Hype	2016
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:9 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles;	2008
Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertension research : official journal of the Japanese Society of Hypertension, 2009, Volume: 32, Issue:8 Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym	2009
[Efficacy of calcium antagonists depending on the functional state of parathyroid glands in patients with hypertensive disease]. Klinicheskaia meditsina, 2009, Volume: 87, Issue:4 Topics: Adult; Amlodipine; Blood Pressure; Calcium; Calcium Channel Blockers; Echocardiography, Doppler; Fem	2009
Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. The American journal of cardiology, 2009, Aug-01, Volume: 104, Issue:3 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Female; Humans; Hypertension; H	2009
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. Heart and vessels, 2009, Volume: 24, Issue:4 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Pr	2009
EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:6 Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D	2009
Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:4 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers;	2009
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal failure, 2010, Volume: 32, Issue:8 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Carotid Arteries; Female; Heart V	2010
Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. Journal of hypertension, 2011, Volume: 29, Issue:2 Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen	2011
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte	2011
Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. Blood pressure. Supplement, 2011, Volume: 1 Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood	2011
Arterial-cardiac destiffening following long-term antihypertensive treatment. American journal of hypertension, 2011, Volume: 24, Issue:10 Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Ankle Brachial Index; Antihypertensive Agents; B	2011
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:1 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie	2012
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study. Vascular health and risk management, 2011, Volume: 7 Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidine	2011
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART. Journal of human hypertension, 2012, Volume: 26, Issue:11 Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur	2012
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:8 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind M	2012
[Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10 Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan	2002
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Internal medicine journal, 2003, Volume: 33, Issue:7 Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon	2003
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation, 2003, Oct-14, Volume: 108, Issue:15 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B	2003
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation, 2003, Oct-14, Volume: 108, Issue:15 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B	2003
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation, 2003, Oct-14, Volume: 108, Issue:15 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B	2003
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation, 2003, Oct-14, Volume: 108, Issue:15 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B	2003
Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. Journal of cardiovascular pharmacology, 2003, Volume: 42, Issue:5 Topics: Adult; Aged; Amlodipine; Analysis of Variance; Biphenyl Compounds; Blood Pressure; Female; Heart Rat	2003
Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993), 2003, Volume: 25, Issue:8 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diastole; Dihydropyri	2003
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. American journal of hypertension, 2004, Volume: 17, Issue:1 Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers;	2004
Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry. American journal of hypertension, 2004, Volume: 17, Issue:5 Pt 1 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black Pe	2004
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. Journal of the American College of Cardiology, 2004, Jun-02, Volume: 43, Issue:11 Topics: Amlodipine; Antihypertensive Agents; Cross-Sectional Studies; Double-Blind Method; Echocardiography;	2004
Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. International journal of clinical practice, 2005, Volume: 59, Issue:3 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Electrocardiography; Female; Fosinopril; Heart Rat	2005
Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:4 Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe	2005
Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:1 Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Female; Humans; Hypertension;	2006
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:3 Topics: Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Glucose; Blood	2006
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart (British Cardiac Society), 2008, Volume: 94, Issue:2 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus	2008
[The effect of lisinopril and amlodipine treatment on left ventricular hypertrophy in hypertensive patients]. Medicinski arhiv, 2006, Volume: 60, Issue:6 Suppl 2 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci	2006
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart and vessels, 2008, Volume: 23, Issue:2 Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Sy	2008
APTH--a trial on ambulatory blood pressure monitoring and treatment of hypertension: objectives and protocol. Acta cardiologica, 1993, Volume: 48, Issue:1 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Blood Pressure Monitors; Dipeptid	1993
Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. Journal of cardiovascular pharmacology, 1995, Volume: 26, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Black People; Blood Pressure; Calc	1995
Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. The American journal of cardiology, 1996, Jul-15, Volume: 78, Issue:2 Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Catecholamines; Diltia	1996
[Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]. Anales de medicina interna (Madrid, Spain : 1984), 1996, Volume: 13, Issue:11 Topics: Amlodipine; Antihypertensive Agents; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Le	1996
Physical performance is preserved after regression of left ventricular hypertrophy. Journal of cardiovascular pharmacology, 1997, Volume: 30, Issue:3 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combin	1997
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood pressure, 1998, Volume: 7, Issue:3 Topics: Aged; Amlodipine; Angiotensin II; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular	1998
Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology, 1999, Volume: 92, Issue:2 Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure;	1999
Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. Journal of hypertension, 2001, Volume: 19, Issue:2 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diastole; Doub	2001
Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. Cardiology, 2001, Volume: 96 Suppl 1 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Echocardiography; Female; Heart Ra	2001
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron, 2002, Volume: 90, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihy	2002
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. Journal of the American Society of Nephrology : JASN, 2002, Volume: 13, Issue:7 Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Creatinine; Echocardiography; Enalapril;	2002
Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:1 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Cro	2002

Article	Year
Uncertain Etiology of Left Ventricular Hypertrophy in a Young Subject With Hypertension Treated With Dexamphetamine. The American journal of medicine, 2020, Volume: 133, Issue:6 Topics: Adult; Amlodipine; Antihypertensive Agents; Cardiomyopathies; Deprescriptions; Dextroamphetamine; Ec	2020
Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertension research : official journal of the Japanese Society of Hypertension, 2015, Volume: 38, Issue:1 Topics: Amlodipine; Animals; Antihypertensive Agents; Dihydropyridines; Drug Evaluation, Preclinical; Drug T	2015
TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993), 2015, Volume: 37, Issue:3 Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Disease Models, Animal; Dis	2015
[Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension]. Kardiologiia, 2016, Volume: 56, Issue:11 Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination;	2016
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:6 Topics: Adrenergic Antagonists; Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calciu	2009
Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis. Journal of the American Geriatrics Society, 2011, Volume: 59, Issue:1 Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Com	2011
Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats. Acta pharmacologica Sinica, 2011, Volume: 32, Issue:9 Topics: Amlodipine; Animals; Antihypertensive Agents; Baroreflex; Biphenyl Compounds; Blood Pressure; Drug S	2011
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. Journal of cardiovascular pharmacology, 2012, Volume: 60, Issue:2 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben	2012
Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection. International journal of molecular medicine, 2012, Volume: 30, Issue:6 Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardioton	2012
Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. Life sciences, 2004, Jul-02, Volume: 75, Issue:7 Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response	2004
Exercise-related syncope induced by vasodilator therapy in an elderly hypertensive patient. Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:2 Topics: Aged; Amlodipine; Exercise; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Syncope; Va	2005
Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients. Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:12 Topics: Activity Cycles; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Ch	2004
Malignant hypertension with intestinal ischemia secondary to juxtaglomerular cell tumor. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:5 Topics: Abdomen, Acute; Acute Kidney Injury; Adenocarcinoma; Adult; Amlodipine; Antihypertensive Agents; Com	2005
Added VALUE of an ancillary study on ambulatory blood pressure monitoring. Journal of hypertension, 2007, Volume: 25, Issue:3 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Heart Ra	2007
Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. Hypertension research : official journal of the Japanese Society of Hypertension, 2007, Volume: 30, Issue:11 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Bloo	2007
Protein synthesis in the hypertrophied heart of spontaneously hypertensive rats and a comparison of the effects of an ACE-inhibitor and a calcium channel antagonist. Cell biochemistry and function, 1995, Volume: 13, Issue:2 Topics: Amlodipine; Animals; Blood Pressure; DNA; Heart Ventricles; Hypertrophy, Left Ventricular; Lisinopri	1995
One-year antihypertensive treatment with amlodipine: effects on 24-hour blood pressure and left ventricular anatomy and function. Acta cardiologica, 1995, Volume: 50, Issue:2 Topics: Adult; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Echocardiography	1995
[The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension]. Minerva cardioangiologica, 1994, Volume: 42, Issue:6 Topics: Amlodipine; Combined Modality Therapy; Diet, Reducing; Evaluation Studies as Topic; Female; Heart Ve	1994
Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. Journal of hypertension, 1993, Volume: 11, Issue:9 Topics: Amlodipine; Animals; Benzazepines; Collagen; Drug Combinations; Hemodynamics; Hypertension; Hypertro	1993
The chronic treatment of amlodipine in regressing hypertrophy. Biochemical Society transactions, 1995, Volume: 23, Issue:3 Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; DNA; Heart Ventricles; Hypertension;	1995
Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. Journal of clinical pharmacology, 1995, Volume: 35, Issue:11 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Blood Pressure Monit	1995
[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation]. Minerva cardioangiologica, 1995, Volume: 43, Issue:10 Topics: Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Viscosity; Calcium	1995
Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension (Dallas, Tex. : 1979), 1997, Volume: 29, Issue:1 Pt 2 Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calci	1997
Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. International journal of cardiology, 1997, Volume: 58, Issue:3 Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Contractile Proteins; Diseas	1997
Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. American journal of hypertension, 1998, Volume: 11, Issue:6 Pt 1 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Enzyme Inhib	1998
Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. Cardiovascular research, 1998, Volume: 37, Issue:3 Topics: Actins; Amlodipine; Animals; Atrial Natriuretic Factor; Blotting, Northern; Calcium Channel Blockers	1998
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. Revista espanola de cardiologia, 1999, Volume: 52 Suppl 3 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block	1999
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. Cardiovascular research, 2000, Volume: 47, Issue:1 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihy	2000
Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats. Journal of cardiovascular pharmacology, 2001, Volume: 37, Issue:1 Topics: Amlodipine; Animals; Calcium Channel Blockers; Heart Failure; Hemodynamics; Hypertrophy, Left Ventri	2001
Comparative effects of atenolol-based and amlodipine-based antihypertensive therapy on QT dispersion in hypertensive subjects. Journal of human hypertension, 2001, Volume: 15 Suppl 1 Topics: Amlodipine; Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hypertension; Hypertroph	2001
Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats. International journal of cardiology, 2001, Volume: 81, Issue:2-3 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito	2001

amlodipine and Left Ventricular Hypertrophy